Market cap
$401 Mln
Revenue (TTM)
$16 Mln
P/E Ratio
2.8
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.1
-
Debt to Equity
0.5
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
99,146,743
9 Years Aggregate
CFO
$-452.62 Mln
EBITDA
$-470.95 Mln
Net Profit
$-515.56 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
X4 Pharmaceuticals (XFOR)
| 1.0 | 1.0 | -6.3 | 7.6 | -53.4 | -51.5 | -- |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
X4 Pharmaceuticals (XFOR)
| -81.8 | -12.5 | -15.5 | -56.6 | -64.4 | -39.9 | -23.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
X4 Pharmaceuticals (XFOR)
|
4.0 | 400.6 | 15.9 | -90.1 | -513.8 | -52.8 | 2.8 | 2.7 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout X4 Pharmaceuticals (XFOR)
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective... antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts. Read more
-
CEO, President & Director
Dr. Paula Ragan Ph.D.
-
CEO, President & Director
Dr. Paula Ragan Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for X4 Pharmaceuticals (XFOR)
What is the current share price of X4 Pharmaceuticals Inc (XFOR) Today?
The share price of X4 Pharmaceuticals Inc (XFOR) is $4.04 (NASDAQ) as of 31-Aug-2026 16:00 EDT. X4 Pharmaceuticals Inc (XFOR) has given a return of -53.39% in the last 3 years.
What is the current PB & PE ratio of X4 Pharmaceuticals Inc (XFOR)?
The P/E ratio of X4 Pharmaceuticals Inc (XFOR) is 2.83 times as on 28-Aug-2026.
The P/B ratio of X4 Pharmaceuticals Inc (XFOR) is 2.70 times as on 28-Aug-2026, a 48 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.58 |
2.37 |
2024 |
-0.13 |
0.22 |
2023 |
-0.05 |
0.11 |
2022 |
-0.04 |
0.05 |
2021 |
-0.02 |
0.03 |
What is the 52 Week High and Low of X4 Pharmaceuticals Inc (XFOR)?
The 52-week high and low of X4 Pharmaceuticals Inc (XFOR) are Rs 4.83 and Rs 2.80 as of 01-Sep-2026.
What is the market cap of X4 Pharmaceuticals Inc (XFOR)?
X4 Pharmaceuticals Inc (XFOR) has a market capitalisation of $ 401 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in X4 Pharmaceuticals Inc (XFOR)?
Before investing in X4 Pharmaceuticals Inc (XFOR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.